文献速递咽喉与嗓音头颈外科小儿耳鼻咽喉

全身贝伐珠单抗治疗复发性呼吸道乳头状瘤病:美国全国调查

Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey.
PubMed 文献 · Laryngoscope · 2017-06-28

给药剂量为5至10 mg/kg,每2至4周一次,全部患者有反应(7/8部分缓解,1/8完全缓解)。全身贝伐珠单抗似在难治性侵袭性乳头状瘤病中显示出希望且并发症少,结果提示应开展正式临床试验。

要点

  • 8例侵袭性RRP患者接受全身贝伐珠单抗,全部有反应(7/8部分缓解,1/8完全缓解)。
  • 4例治疗后胸部影像中3例改善、1例稳定,7例可延长治疗间隔并维持临床反应。
  • 并发症少(咯血1例,蛋白尿1例),1例长期肺部病变者在治疗中发现恶变。

核心结论

  • 全身贝伐珠单抗似在最具治疗抵抗性和侵袭性的乳头状瘤病中显示出显著希望,且并发症谱低。
  • 这些结果提示贝伐珠单抗应在RRP中开展正式临床试验。

研究设计与样本

  • 病例系列(证据等级4),通过电子问卷调查美国小儿耳鼻咽喉科学会RRP工作组、美国支气管食管学会及作者已知使用过全身贝伐珠单抗治疗RRP的医生。

主要发现

  • 8例接受治疗者均为手术和辅助治疗无法控制的侵袭性乳头状瘤病,其中7/8例有肺部病变。
  • 给药剂量范围为5至10 mg/kg,每2至4周一次,全部患者有反应(7/8部分缓解,1/8完全缓解)。
  • 4例有贝伐珠单抗后胸部影像者中,3例疾病改善、1例稳定。
  • 7例可延长治疗间隔并维持临床反应。
  • 1例长期肺部病变(>10年)者在治疗期间诊断为恶变,停用贝伐珠单抗改用其他化疗药物;其余患者继续全身贝伐珠单抗,并发症轻微(咯血n=1,蛋白尿n=1)。

关键数值与推荐

  • 给药剂量范围为5至10 mg/kg,每2至4周一次。
  • 全部8例患者有反应:7/8部分缓解,1/8完全缓解。
  • 4例有贝伐珠单抗后胸部影像者中,3例改善、1例稳定。
  • 7例可延长治疗间隔并维持临床反应。
  • 并发症:咯血n=1,蛋白尿n=1。

临床怎么用

  • 全身贝伐珠单抗似可用于手术和辅助治疗无法控制的侵袭性RRP,尤其是有肺部病变者。
  • 治疗期间可延长给药间隔并维持临床反应。
  • 结果提示应在RRP中开展正式临床试验。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: Aggressive laryngeal, tracheal, and pulmonary papilloma is an extremely challenging clinical problem without proven treatment options. A recent German report documented promising results with systemic bevacizumab. The objective of this study is to report the initial experience of this novel treatment in the United States for recurrent respiratory papillomatosis (RRP). STUDY DESIGN: Cases series. METHODS: Electronic survey of the RRP Task Force of the American Society of Pediatric Otolaryngology, American Broncho-Esophagological Association, and physicians known to the authors to have used systemic bevacizumab for RRP. RESULTS: Eleven completed surveys were obtained. In three cases, systemic bevacizumab was considered clinically but not administered. Eight patients were treated with systemic bevacizumab, all for aggressive papillomatosis uncontrolled by surgical and adjuvant therapy, including seven of eight with pulmonary disease. Treatment dosing ranged from 5 to 10 mg/kg every 2 to 4 weeks, with all patients responding (7/8 partial response, 1/8 complete response). In four patients who had postbevacizumab chest imaging, three demonstrated improvement of disease and one stabilization. Treatment interval could be lengthened in seven patients and clinical response maintained. One patient with long-standing pulmonary disease (>10 years) was diagnosed with malignant transformation while on treatment, and bevacizumab was discontinued in lieu of other chemotherapeutic agents. All other patients continue on systemic bevacizumab with minimal complications (hemoptysis n = 1, proteinuria n = 1). CONCLUSIONS: Systemic bevacizumab appears to have significant promise in the most treatment-resistant and aggressive forms of papillomatosis with a low complication profile. These results suggest bevacizumab should be studied in a formal clinical trial for RRP. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:2225-2229, 2017.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Best SR, Mohr M, Zur KB, et al. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey. Laryngoscope. 2017. PMID: 28657692. doi:10.1002/lary.26662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。